常染色体显性多囊肾病小鼠模型妊娠期及哺乳期线粒体药物治疗:对母鼠及其子代均有益
Mitochondrial pharmacotherapy during pregnancy and lactation in an ADPKD mouse model: a win for both mothers and their offspring.
PubMed 文献 · Kidney Int · 2022-01-01
常染色体显性多囊肾病患者缺乏妊娠期安全的药物治疗。本期Daneshgar等在小鼠模型中发现,妊娠期及哺乳期给予线粒体保护肽elamipretide无致畸性,并减轻母鼠及受累子代的疾病严重程度。该发现提示elamipretide在妊娠期、宫内及出生后早期具有治疗潜力。
要点
- 常染色体显性多囊肾病患者缺乏妊娠期安全的药物治疗。
- 小鼠模型中妊娠期及哺乳期给予elamipretide无致畸性。
- elamipretide减轻母鼠及受累子代的疾病严重程度。
核心结论
- Daneshgar等揭示妊娠期及哺乳期给予elamipretide在小鼠模型中无致畸性,并减轻母鼠及受累子代的疾病严重程度。
- 该发现提示elamipretide在妊娠期、宫内及出生后早期具有治疗潜力。
研究设计与样本
- 常染色体显性多囊肾病小鼠模型研究,妊娠期及哺乳期给予线粒体保护肽elamipretide。
主要发现
- 妊娠期及哺乳期给予elamipretide无致畸性。
- elamipretide减轻母鼠及受累子代的疾病严重程度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacotherapies that are safe during pregnancy are lacking for patients with autosomal dominant polycystic kidney disease. In this issue, Daneshgar et al. reveal that administration of the mitochondrial-protective peptide, elamipretide, during pregnancy and lactation in a mouse model with autosomal dominant polycystic kidney disease, is nonteratogenic and attenuates disease severity in both mothers and their affected offspring. This finding suggests therapeutic potential of elamipretide during pregnancy, in utero, and in early postnatal life.
来源:Kidney Int,查看原文。版权归原作者所有。
引用
- Wang W, Tran PV. Mitochondrial pharmacotherapy during pregnancy and lactation in an ADPKD mouse model: a win for both mothers and their offspring. Kidney Int. 2022. PMID: 35461611. doi:10.1016/j.kint.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。